The RET/PTC1 oncogene, a rearranged form of the RET proto-oncogene, has been reported to be associated with human papillary thyroid carcinomas. We have shown that targeted expression of RET/PTC1 in the thyroid gland leads to the development of thyroid carcinomas in transgenic mice with histologic and cytologic similarities to human papillary thyroid carcinoma. To further investigate how RET/PTC1 expression contributes to the pathogenesis of papillary thyroid tumor, the time of tumor onset and the early phenotypic consequences of RET/PTC1 expression in thyrocytes were determined. All high copy transgenic mice developed bilateral thyroid tumors as early as 4 days of age. At embryological days 16 ± 18, increased proliferation rate, distorted thyroid follicle formation and reduced radioiodide concentrating activity were identi®ed in transgenic embryos. The reduced radioiodide concentrating activity was attributed to decreased expression of the sodium-iodide symporter. Our study showed that RET/ PTC1 not only increased proliferation of thyrocytes, it also altered morphogenesis and dierentiation. These ®ndings provide a model for the role of RET/PTC1 in the formation of abnormal follicles with reduced iodide uptake ability observed in human papillary thyroid carcinoma.
Dierentiated thyroid tumors derived from follicular cells in humans are subdivided into papillary and follicular thyroid carcinomas. These two tumor types have dierences in cytological nuclear features, etiology, clinical behavior and oncogene involvement. In areas where dietary iodine is sucient, papillary thyroid carcinoma (PC) accounts for about 80% of thyroid cancers. For patients who had previous radiation exposure, PC occurs frequently. A dramatic increase in PC was recently found in children who were exposed to radiation from the Chernobyl nuclear reactor accident. Among oncogenes studied, the RET/ PTC oncogenes are uniquely restricted to PCs (Grieco et al., 1990; Jhiang and Mazzaferri, 1994; Santoro et al., 1992) . The prevalence of RET/PTC in spontaneous PCs ranges from 3 ± 35% depending on geographic areas. However, RET/PTC is detected in about 70% of Chernobyl-related thyroid tumors (Klugbauer et al., 1995) .
The RET/PTC oncogenes are rearranged forms of the RET proto-oncogene (RET), which encodes a receptor tyrosine kinase. The ligands of RET have been recently identi®ed as glial cell line-derived neurotrophic factor GDNF (Lindsay and Yancopoulos, 1996; Vega et al., 1996) and neurturin (Buj-Bello et al., 1997; Klein et al., 1997) , for which RET serves as a signaling component for the corresponding receptor complex. Three dierent activating genes, H4 (D10S170 locus), RIa, and ele1 have been shown to rearrange with RET to form RET/PTC1, RET/PTC2 and RET/PTC3, respectively. In each case, the intracellular domain of RET, which has tyrosine kinase activity, was fused to the N-terminus of the activating gene that is capable of dimerization. Consequently, the RET/PTC chimeric oncogenes are constitutively expressed and activated in thyroid follicular cells (Tong et al., 1997) .
To investigate whether RET/PTC causes PC, we have generated a transgenic mouse model of PC with targeted expression of RET/PTC1 in the thyroid gland using the bovine thyroglobulin (Tg) promoter. Our studies focused on two transgenic lines, diering in the relative copy number of inserted transgene. All transgenic ospring from these two lines developed bilateral thyroid tumors with considerable similarities to human PCs, particularly in the nuclear cytological features and the presence of local invasion . Our results indicate that RET/PTC1 is a speci®c genetic lesion that leads to the development of PCs.
In this paper, we focused our investigation on the high copy transgenic mice to determine the time of tumor onset, to identify the cellular abnormalities preceding tumor development, to analyse the expression of thyroid-speci®c markers, and to examine the role of thyroxine (T4) supplementation in tumor progression.
The time of tumor onset was determined in both high copy and low copy transgenic mice. All high copy transgenic mice had bilateral thyroid tumors by 4 days of age, yet all low copy transgenic mice had bilateral thyroid tumors with similar phenotypes by 21 days of age. At 4 days of age, the thyroid glands in nontransgenic littermates contained round or ovoid thyroid follicles ®lled with colloid, and the nuclei of thyrocytes were round and regularly shaped, with a normal chromatin organization (Figure 1a and c) . In contrast, high copy transgenic mice had bilateral thyroid carcinomas (Figure 1b ) with regions containing papillary projections of neoplastic cells with high cellular density (Figure 1d ). Nuclei were enlarged, highly vesicular, round to oval in shape, and contained occasional nuclear grooves and pseudoinclusions. Foci of spindle cells without formation of identi®able follicles were sometimes found within the thyroid tumors. Thyroid tumors in transgenic mice tended to arise from the central portions of the thyroid lobes with peripheral areas frequently containing irregular, dilated follicles (Figure 1b) . Interestingly, the thyrotropin receptor (TSHR) was expressed at a higher level in the central regions of the thyroid glands of both non-transgenic and transgenic mice as demonstrated by immunohistochemical staining (data not shown). Furthermore, thyroid tumor development and progression was delayed in both high copy (Figure 1e and f) and low copy transgenic mice (Sagartz et al., manuscript in preparation) by administration of exogenous T4.
Cellular abnormalities preceding tumor development were investigated in high copy transgenic mice. In the mouse, the Tg promoter is known to be active from the embryological day 14.5 (E14.5) (Zannini et al., 1997) , and the thyroid glands begin to form follicles at E14.5. At E16.5, while primitive and less de®ned follicles were found in the thyroid glands of nontransgenic littermates (Figure 2a ), large and irregular thyroid follicles were identi®ed in high copy transgenic embryos (Figure 2b ). At E18, the thyroid glands of non-transgenic littermates had small, round, and Figure 1 (a ± d): H&E staining of thyroid glands from non-transgenic (a and c) and transgenic mice (b and d) at 4 days of age. Nontransgenic mice showed round thyroid follicles with cells of dense nuclei. Transgenic mice had bilateral thyroid tumors with increased cellular density and irregularly shaped, hypochromatic nuclei. c and d (bars=20 mm) are higher magni®cation of a and b (bars=500 mm). (e and f) H&E staining of thyroid glands from a transgenic mouse at 4 months of age fed a normal diet (e), and a transgenic mouse at 5 months of age fed a T4-supplemented diet (f). The transgenic mouse fed a T4-supplemented diet had cystic thyroid tumors with less cellularity, and the tissue was primarily composed of distended follicles ®lled with colloid (e and f: bars=1 mm). Both normal rodent diet (LM-485) and T4-supplemented diet (TD-95053) were obtained from Harlan Teklad (Madison, WI, USA) de®nitive follicles ®lled with colloid (Figure 2c) , while large distorted thyroid follicles with little colloid were found in transgenic embryos ( Figure 2d ). The proliferation rate of thyroid follicular cells at dierent stages was evaluated by measuring the percentage of cells labeled with BrdU. At E16.5, the BrdU index of transgenic thyroids was 15.74+0.67% (Figure 2b ), as compared with non-transgenic thyroids which had a BrdU index of 9.09+0.70% (Figure 2a) . In comparison with non-transgenic thyroids, which had very little cell turnover after 2 ± 3 weeks of age, the BrdU index of transgenic thyroids was maintained at a higher level throughout life although it decreased progressively (data not shown).
In addition to developing early-onset bilateral thyroid carcinomas, all high copy transgenic mice had marked congenital hypothyroidism . Iodide, an essential component of thyroid hormones, is concentrated 20 ± 40-fold with respect to the iodide concentration in plasma. To investigate the mechanisms underlying congenital hypothyroidism, radioiodide concentrating activity was studied in high copy transgenic embryos after intraperitoneal injection of Na-125 I into pregnant dams. At E18, while radio- More cells were undergoing proliferation in the thyroid glands of the transgenic embryo compared to non-transgenic embryo. (a and b: bars=100 mm). Bromo-deoxyUridine (BrdU) was injected intra-peritoneally (i.p.) into mice at 100 mg/g of body weight 1 h prior to sacri®ce. Cells labeled with BrdU were identi®ed by immunohistochemical staining using 1 : 400 dilution of anti-BrdU monoclonal antibodies (Harlan Bioproducts for Science). BrdU index of the tissues studied was analysed by a computer image analyzer (Roche Pathology Workstation, Elon College, NC, USA). (c and d) Anti-thyroglobulin immunostaining of thyroid sections from nontransgenic (c) and transgenic (d) embryos at E18.0 day. In the transgenic embryo, there were large and distorted thyroid follicles with multiple layers of thyroid follicular cells and little colloid. (c and d: bars=20 mm) (e and f) Radioiodide concentrating activity in the thyroid glands of non-transgenic (e) and transgenic (f) embryos at E18.0 day. The thyroid glands of high copy transgenic embryo had greatly reduced radioiodide concentrating activity with only occasional silver grains. (e and f: bars=100 mm). Na-125 I (Amersham, Arlington Heights, IL, USA) was injected i.p. into pregnant dams at 0.3 mCi/g of body weight 6 h prior to sacri®ce. Thyroid tissue sections (3 mm) were generated, and micro-autoradiography emulsion was performed using LM1 emulsion solution (Amersham). Slides were exposed at 48C for 3 ± 8 days and were counterstained with hematoxylin iodine concentrating activity was evident in nontransgenic littermates (Figure 2e) , it was greatly reduced in high copy transgenic embryos, as only a few silver grains were observed to be scattered in small portions of thyroid follicles (Figure 2f ). Radioiodide concentrating activity was reduced in the thyroid glands of high copy transgenic mice at all ages. A high copy transgenic mouse of 7 months of age, originally fed with a T4-supplemented diet and then switched to a normal diet 1 week before sacri®ce, had only minimal radioiodide concentrating activity at the periphery of the thyroid gland (Figure 3b ), whereas the thyroid glands of the age-matched non-transgenic mouse showed abundant radioiodide concentrating activity (Figure 3a) .
The iodide concentrating activity in the thyroid glands is contributed by two distinct processes, active iodide uptake across the basolateral membrane of thyroid follicular cells and iodide organi®cation to further sequester iodide in the form of colloid. In high copy transgenic mice, total iodide uptake activity in the thyroid glands was 30-fold lower than those of agematched non-transgenic mice (Figure 4a ), despite the fact that serum TSH level was greatly elevated in high copy transgenic mice due to congenital hypothyroidism . Under T4-supplemented dietary conditions, when serum T4 and TSH levels in high copy transgenic mice were comparable to those of nontransgenic mice (data not shown), total iodide uptake activity in the thyroid glands of high copy transgenic mice was sevenfold lower than those of non-transgenic mice (Figure 4a) . In non-transgenic mice, iodide uptake activity was decreased by T4 supplementation (Figure  4a ), con®rming that iodide uptake activity is TSH dependent. However, in high copy transgenic mice, there was no signi®cant dierence in iodide uptake activity between mice fed with normal diet and T4-supplemented diet (Figure 4a ). This observation suggests that the stimulatory eect of TSH on iodide uptake appeared to be surpassed by the suppressive eect of increased expression of RET/PTC1 in high copy transgenic mice. There was no signi®cant dierence in the eciency of iodide organi®cation between high copy transgenic mice and non-transgenic mice (Figure 4b , 89+3.0% versus 91+4.3%).
Active iodide uptake activity in thyroid follicular cells is mainly mediated by the Na + /I 7 symporter (NIS) (Dai et al., 1996; Smanik et al., 1996) . The NIS S-labeled riboprobe in thyroid glands from non-transgenic (c) and transgenic (d) mice at 1 month of age. The mRNA level of NIS was reduced in the thyroid glands of transgenic mice compared with those of non-transgenic mice. No background signal was detected when the sense riboprobe was used as control (data not shown). (c and d: bars=50 mm). A 160 bp mNIS cDNA fragment was ampli®ed by PCR using mouse thyroid cDNA as template with primers: mNIS-F2: GAG CTC GCT CAA TTC GCT GCT CAT AG and mNIS-R2: GGT ACC TCA CGA TGC CAG TAT ACA GC. This cDNA fragment was subcloned into pBluescript (Stratagene, La Jolla, CA, USA). Sense or anti-sense riboprobes were synthesized by in vitro transcription using T7 or T3 RNA polymerase (Stratagene) in the presence of 35 S-UTP. The thyroid glands were ®xed in 10% formalin overnight and paranembedded 10 mm tissue sections were generated. The tissue sections were post-®xed with 4% paraformaldehyde, treated with proteinase K and acetylated. Hybridization was carried out overnight at 558C with hybridization solution containing sense or antisense mNIS riboprobe (1610 7 c.p.m./ml). The slides were then washed at 508C in a solution containing Denhardt's, 10 mM DTT and 50% formamide, and autoradiography was performed as described in Figure 2 except a longer exposure time of 8 ± 14 days mRNA level was reduced in the thyroid glands of high copy transgenic mice, when compared with those of non-transgenic mice, as demonstrated by in situ hybridization (Figure 3c and d) and semi-quantitative RT ± PCR analysis (Figure 4c , middle panel). In both transgenic and non-transgenic mice, the NIS mRNA level was lower in the thyroid glands of mice fed a T4-supplemented diet than mice fed a normal diet, indicating that NIS expression is up-regulated by elevated serum TSH level. For non-transgenic (WT) mice and PTC1+T4 mice, the total iodide uptake activity of thyroid glands (Figure 4a ) is in agreement with the NIS expression level (Figure 4c ). However, total iodide uptake activity of PTC1 mice appears to be lower than that of WT+T4 mice, despite the fact that the NIS mRNA expression level of PTC1 mice is higher than that of WT+T4 mice. This result suggests that, while NIS expression is stimulated by elevated TSH level in RET/PTC1 mice, the increased expression of RET/PTC1 may inhibit NIS function at the posttranscriptional level.
As expected, RET/PTC1 was not expressed in the thyroid glands of non-transgenic mice, but it was expressed in the thyroid carcinomas of high copy transgenic mice (Figure 4c, top panel) . RET/PTC1 expression was higher in the thyroid tumors of transgenic mice fed a normal diet than those of transgenic mice fed a T4-supplemented diet. Finally, the TPO mRNA level in the thyroid glands was comparable among all mice investigated (Figure 4c , bottom panel), which correlates the observed equivalent eciency of iodide organi®cation. Therefore, RET/ PTC1 appeared to have little eect, if any, on TPO expression and iodide organi®cation.
The time of tumor onset in RET/PTC1 transgenic mice appears to depend on the expression level of RET/PTC1. All high copy transgenic mice had earlier tumor onset than low copy transgenic mice. Furthermore, thyroid tumors in transgenic mice arose in the central portions of the thyroid lobes, where the TSHR is highly expressed. Since the bovine Tg promoter used to drive RET/PTC1 expression in transgenic mice is stimulated by TSH, RET/PTC1 expression is expected Figure 4 (a and b): Radioiodide uptake (a) and radioiodide organi®cation (b) in the thyroid glands of transgenic and nontransgenic mice fed a normal diet or a T4-supplemented diet. WT: non-transgenic mice fed a normal diet (n=5). WT+T4: nontransgenic mice fed a T4-supplemented diet (n=4). PTC1: transgenic mice fed a normal diet (n=5). PTC1+T4: transgenic mice fed a T4-supplemented diet (n=4). Mice were injected with Na-125 I and sacri®ced as described in Figure 2 . Isolated thyroid tissues were then minced and homogenized in 0.5 ml of ice-cold 0.1 M NaOH. The radioactivity of tissue homogenates was counted by a g-counter, and this value was referred as total iodide uptake. The supernatants of thyroid homogenates were subjected to TCA (5% w/v) precipitation to measure the proteinbound 125 I to evaluate iodide organi®cation in vivo (Bachrach et al., 1985) . Organi®ed 125 I was expressed as the percentage of total iodide uptake measured prior to TCA precipitation. (c) RT ± PCR analysis for the expression of RET/PTC1, mouse sodium-iodide symporter (mNIS), and mouse thyroperoxidase (mTPO). A ubiquitously expressed gene, mouse b 2 -microglobulin (mb 2 -MG), was included in each PCR reaction as an internal control. WT: pooled thyroid glands from four non-transgenic mice at 5 months of age fed a normal diet. WT+T4: pooled thyroid glands from four non-transgenic mice at 5 months of age fed a T4-supplemented diet. PTC1: thyroid gland from a transgenic mouse at 12 months of age fed a normal diet. PTC1+T4: thyroid gland from a transgenic mouse at 12 months of age fed a T4-supplemented diet. Total RNAs, extracted from frozen thyroid tissues were reverse transcribed and used for PCR ampli®cation using the following primers: for RET/PTC1, TPC-4: GTC GGG GGG CAT TGT CAT CT and KD-2: AGT TCT TCC GAG GGA ATT CC, which amplify a DNA fragment of 203 bp; for mouse Na + /I 7 symporter (mNIS), mNIS-F1: GCT CAA TTC GCT GCT CAT AG and mNIS-R1: AAG TCC ATC AGG TTG ATC CG, which amplify a DNA fragment of 420 bp; for mouse thyroperoxidase (mTPO), mTPO-F1: GAG CTC CGC CCT GCT TCC TGG CTG GA and mTPO-R2: GGT ACC ATG GTG ATG ATC TGG TGC, which amplify a DNA fragment of 202 bp; for mouse b 2 -microglobulin (mMG), mMG-F1: TGT CAG ATA TGT CCT TCA GC and mMG-R1: GAA GGT GAT GTG TAC ATT GC, which amplify a DNA fragment of 265 bp. The PCR cycling conditions were: one cycle at 948C for 3 min, followed by 35 cycles at 948C for 30 s, 568C for 30 s, and 728C for 2 min, and followed by one cycle at 728C for 8 min to be higher in cells with greater expression of TSHR. Taken together, the early tumor onset in high copy transgenic mice was contributed by high expression of RET/PTC1 in cells with high proliferation capacity and sustained elevation of serum TSH.
The proliferation rate of thyroid follicular cells in high copy transgenic mice appeared to be determined by the interplay among RET/PTC1 expression, serum TSH levels, and the intrinsic programming of declining proliferation capacity in mature thyroid cells. Thyroid follicular cells in high copy transgenic mice had a higher proliferation rate than cells in non-transgenic littermates at E16.5 (Figure 2a and b) . Since the pituitary-thyroid axis in the fetus is not established until late gestation (Jokinen and Botts, 1994) , the early onset of increased proliferation in the thyroids of high copy transgenic mice indicates that RET/PTC1 stimulates proliferation in thyroid cells. Indeed, others have reported that RET/PTC expression stimulates proliferation in primary human thyrocytes (Bond et al., 1994) . In high copy transgenic mice, serum TSH levels were greatly elevated due to congenital hypothyroidism. Therefore, the increased proliferation rate in the thyroid follicular cells of high copy transgenic mice may also result from TSH stimulation. However, despite the persistence of elevated TSH levels in high copy transgenic mice, the proliferation rate of thyroid follicular cells in transgenic mice declined gradually with age (data not shown). This suggests that the intrinsic programming for declining proliferation capacity in mature thyroid cells antagonizes the stimulative eects of RET/PTC1 and TSH on proliferation rate.
The signaling pathways leading to thyroid follicle formation during development appear to be disturbed by RET/PTC1-activated signaling pathways. Distorted follicle formation could be identi®ed in the thyroid glands of high copy transgenic mice as early as E16.5. It has been reported that thyroid follicle formation in cultured primary porcine thyroid cells was promoted by TSH-cAMP mediated signaling pathways, but was blocked by tyrosine kinase mediated signaling pathways (Yap et al., 1997) . Furthermore, aberrant tyrosine kinase activity, including chimeric oncoproteins of RET and TRK, as well as deregulation of MET, has been frequently found in human PCs (Bongarzone et al., 1996; Di Renzo et al., 1992; Santoro et al., 1995) . In PCs, thyroid follicles are improperly or incompletely formed due to papillary infoldings. These ®ndings suggest that tyrosine kinase-mediated signaling pathways have an adverse eect on the maintenance of thyroid follicular structure, and this may explain why aberrant tyrosine kinase activity is frequently associated with PCs.
The iodide uptake activity in thyroid follicular cells appears to be inhibited by RET/PTC1 expression. Our study suggests that the reduced iodide uptake in RET/ PTC1 expressing cells is contributed at least in part by the decreased NIS expression. Indeed, our previous study showed that NIS expression was decreased in human PCs (Smanik et al., 1997) . Since radioiodide has been used to detect and to treat recurrent and metastatic disease in patients with thyroid cancers, it will be of clinical signi®cance to determine the molecular mechanisms underlying the loss of iodide uptake activity in thyroid cancers.
The reduced iodide uptake activity in thyroid follicular cells accounts, at least in part, for the phenotype of congenital hypothyroidism in high copy transgenic mice. Consequently, it also contributes to the early tumor onset in high copy transgenic mice by increasing serum TSH levels, which in turn leads to higher RET/PTC1 expression and higher proliferation rate in the thyroid follicular cells of high copy transgenic mice. Therefore, the initial expression level of RET/PTC1 in the thyroid glands of transgenic embryos plays an important role in determining tumor formation in RET/PTC1 transgenic mice.
It is noteworthy that RET/PTC1 is a somatic acquired event in human PCs whereas RET/PTC1 is predisposed as a germ-line genetic determinant in our transgenic mouse model. Furthermore, the expression level of RET/PTC1 in the thyroid tumors of high copy RET/PTC1 transgenic mice may be higher than that in human PCs. Therefore, thyroid tumors developed in the RET/PTC1 transgenic mice are not completely representative to human PCs.
Nevertheless, we have shown that RET/PTC1 expression in the thyroid glands of transgenic mice leads to the development of thyroid tumors with many features similar to human PCs. Further characterization of the thyroid glands of RET/PTC1 transgenic mice demonstrated several distinctive cellular changes preceding tumor development, including an increased proliferation rate, abnormal thyroid follicle formation, and reduced iodide concentrating activity. These ®ndings provide a model for the role of RET/PTC1 in the formation of abnormal follicles with reduced iodide uptake ability observed in human PCs. It will be of great interest to further investigate which signaling pathway(s) perturbed by RET/PTC1 expression are responsible for these distinctive cellular changes and which signaling pathway(s) are essential for RET/PTC1 to induce tumors with many characteristics of PCs.
In addition, our data indicates that thyroid tumor development and progression in RET/PTC1 transgenic mice is primarily determined by the expression levels of RET/PTC1 in thyrocytes. Signaling pathways perturbed by RET/PTC1 in thyrocytes could conceivably be overcome by other factors, if RET/PTC1 expression occurs at a low level. Therefore, both the intensity and duration of RET/PTC1 activation in proliferating thyroid follicular cells may be essential to confer thyroid tumor development in transgenic mice as well as in humans.
